LIST OF BINDING INTERFACES for query 'DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1' in category 'PROTEIN NAME'

(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
PDB Ligand Drug Indication Macromolecule/
Organism
Pfam Binding_Interfaces (View) Details
4an2 EUICobimetinib
(DB05239)
Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1
(Homo sapiens)
Pkinase
4lmn EUICobimetinib
(DB05239)
Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1
(Homo sapiens)
Pkinase
4u7z 3EWSelumetinib
(DB11689)
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN).DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1
(Homo sapiens)
Pkinase
7jur QOMTrametinib
(DB08911)
Trametinib is a kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer.DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1;
KINASE SUPPRESSOR OF RAS 2
(Homo sapiens;
oryctolagus cuniculus
)
PK_Tyr_Ser-Thr
Pkinase
7m0u QO7Binimetinib
(DB11967)
Binimetinib is a medication used to treat metastatic melanoma with specific mutations.DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1
(Homo sapiens)
Pkinase
PDB Ligand Drug Indication Macromolecule/
Organism
Pfam Binding_Interfaces (View) Details